Dicerna Pharmaceuticals

Dicerna is applying its proprietary RNAi technology to discover and develop innovative treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. This second-generation gene-silencing technology can knock down the expression of a targeted gene in a way that is highly selective, specific and more potent than other RNAi approaches. The company's lead programme is currently in Phase I trials as a potential cancer treatment. Dicerna went public in January 2014.